Study of remibrutinib for secondary progressive multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests an oral medication called remibrutinib to see if it can slow disability progression in people with secondary progressive multiple sclerosis (SPMS). You might join if you have had MS for a while, your symptoms have worsened over the past year, and you haven't had any recent relapses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a diagnosis of secondary progressive multiple sclerosis (SPMS) with confirmed disability worsening in the last year.
- You have not had any MS relapses in the past 2 years.
- Your walking ability is affected but you can still walk with or without an aid (EDSS score 3 to 6).
- You are able to have MRI scans without metal implants or claustrophobia issues.
- You are not pregnant, breastfeeding, or at risk of pregnancy without using effective birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called TRX319 for people with progressive multiple sclerosis (MS) that has been getting worse. The study wants to see if this treatment can help slow down disability progression.
This trial tests whether the drug rituximab can help people with secondary progressive MS keep their thinking and hand abilities from getting worse. It is for people with more advanced disability.
This study looks at how well BRIUMVI (a medicine for relapsing multiple sclerosis) works for people in everyday life. Researchers want to see how people do when they first start the medication.
This trial tests an oral drug called remibrutinib to see if it can help people with relapsing or progressive multiple sclerosis. It uses brain scans (MRI) to track how well the drug works.
This study tests an oral medication called orelabrutinib for people whose multiple sclerosis has changed from relapsing-remitting to secondary progressive. The goal is to see if it can slow down disability worsening that happens even without relapses.
This study tests a new oral medication called remibrutinib for people with relapsing multiple sclerosis who are currently on Ocrevus. Participants will switch from Ocrevus to remibrutinib to see if it is safe and effective.
Hear when a new Secondary Progressive Multiple Sclerosis (SPMS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.